Literature DB >> 9076747

Stereoselective effects-of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies.

D Lodge1, A Bond, M J O'Neill, C A Hicks, M G Jones.   

Abstract

The stereoselectivity and potency of 3N-substituted 2,3-benzodiazepines were examined in vivo against excitation of spinal neurones induced by electrophoretic ejection of N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and kainate in anaesthetised rats. AMPA receptor antagonist activity resided in the (-) isomers, LY300164 and LY303070, which were effective given electrophoretically, intravenously (2.5-5 mg/kg) or orally (10 mg/kg). The same stereoselectivity was observed in neuroprotection studies. Thus, systemic administration of the (-) isomer, but not the (+) isomer, of these 2,3-benzodiazepines before or immediately after bilateral carotid artery occlusion in the gerbil was neuroprotective. For example, 10 mg/kg of LY300164 intraperitoneally or orally provided survival of up to 25% of hippocampal CA1 neurones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9076747     DOI: 10.1016/s0028-3908(96)00155-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Mechanism of inhibition of GluA2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives: functional consequences of replacing a 7,8-methylenedioxy with a 7,8-ethylenedioxy moiety.

Authors:  Mohammad S Qneibi; Nicola Micale; Silvana Grasso; Li Niu
Journal:  Biochemistry       Date:  2012-02-13       Impact factor: 3.162

Review 2.  Talampanel.

Authors:  John F Howes; Cynthia Bell
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

3.  Mechanism of inhibition of the GluA2 AMPA receptor channel opening: consequences of adding an N-3 methylcarbamoyl group to the diazepine ring of 2,3-benzodiazepine derivatives.

Authors:  Congzhou Wang; Zhenyu Sheng; Li Niu
Journal:  Biochemistry       Date:  2011-07-28       Impact factor: 3.162

Review 4.  Treatment of Parkinson's disease : what's on the horizon?

Authors:  Stacy S Wu; Steven J Frucht
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

6.  Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.

Authors:  Congzhou Wang; Li Niu
Journal:  ACS Chem Neurosci       Date:  2013-02-12       Impact factor: 4.418

7.  Comparison of the AMPA antagonist action of new 2,3-benzodiazepines in vitro and their neuroprotective effects in vivo.

Authors:  Gábor Kapus; Szabolcs Kertész; Gábor Gigler; Annamária Simó; Miklos Vegh; József Barkóczy; László G Hársing; Géza Szabó; György Lévay
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

8.  Neuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal models.

Authors:  G Gigler; K Móricz; M Agoston; A Simó; M Albert; A Benedek; G Kapus; S Kertész; M Vegh; J Barkóczy; B Markó; G Szabó; E Matucz; I Gacsályi; G Lévay; L G Hársing; G Szénási
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.